Iberdomide Combination Therapy
Phase 1/2 Trial of Elotuzumab, Daratumumab, Iberdomide, and Dexamethasone for Relapsed Multiple Myeloma
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1/2
- Enrollment
- 37 patients (estimated)
- Sponsors
- Mayo Clinic
- Tags
- Cereblon E3 Ligase Modulators (CELMoDs), Quadruplet Therapy
- Trial Type
- Treatment
- Last Update
- SparkCures ID
- 2042
- NCT Identifier
- NCT06785415
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.